CHANCE and SAMPRAS Trials in Neurology
I cannot provide specific information about "Chance point and Sampras trials" as these do not appear to be established neurological trials in the medical literature provided or in standard neurology nomenclature.
What I Found Instead
The CHANCE trial is a well-established stroke prevention study, but there is no recognized "SAMPRAS" trial in neurology. 1
The CHANCE Trial (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events)
For patients with minor ischemic stroke or high-risk TIA, dual antiplatelet therapy with clopidogrel plus aspirin for 21-30 days significantly reduces recurrent stroke risk compared to aspirin alone. 1
Key Evidence from CHANCE:
The trial demonstrated that clopidogrel (75 mg/day) plus aspirin (75 mg/day) reduced 90-day stroke recurrence from 11.7% to 8.2% (HR 0.68,95% CI 0.57-0.81, p<0.001) in Chinese patients with minor stroke or TIA. 1
A post-hoc analysis showed no difference in the beneficial effect of dual antiplatelet therapy versus single antiplatelet therapy specifically in patients with versus without intracranial atherosclerotic disease. 1
Current guidelines recommend dual antiplatelet therapy (clopidogrel plus aspirin) for 21-30 days in very high-risk TIA patients (ABCD2 score >4) or minor stroke (NIHSS 0-3) of non-cardioembolic origin, followed by antiplatelet monotherapy. 1
Clinical Application:
- Loading dose: Aspirin 160 mg immediately after brain imaging excludes hemorrhage 1
- Maintenance: Clopidogrel 75 mg + aspirin 75-81 mg daily for 21-30 days 1
- After 21-30 days: Switch to single antiplatelet agent (aspirin or clopidogrel alone) 1
Regarding "SAMPRAS"
No trial by this name exists in the neurological literature. You may be referring to:
SAMMPRIS (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis) - which demonstrated that aggressive medical management is superior to intracranial stenting for symptomatic intracranial atherosclerotic disease 1
SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) - which compared carotid stenting to endarterectomy in high-risk patients 1
If you can clarify which specific trial or neurological condition you're asking about, I can provide more targeted guidance.